On February 19, Steve Kramer replied to Stavros:

As in so many such studies, the medication is given to a cohort of
patients who are, as my med onc puts it, on their last legs, in
desperate condition.

Such appears to the case here: "The research involved 127 men, aged 47
to 85, with metastatic prostate cancer. None of the men had symptoms
from the cancer, such as pain. The men no longer were responding to
traditional hormone treatment for prostate cancer."

Another instance is that of the trials of docetaxel (Taxotere), in which
the cohort under study was much the same as this one.

To me, what this means is that until/unless I am in a condition like
that of the study cohorts, I should be able to anticipate a much better
outcome.

Regards,

Steve J

"Do not go where the path may lead, go instead where there is no path
and leave a trail."
-- Ralph Waldo Emerson

Which is what the brave and selfless men in such cohorts have done for
the rest of us. They must not be forgotten.

Yes, but these guys all had metastatic cancer, and "Perhaps more significant
were the results seen three years after the vaccine was given. At that
point, 34% of vaccine patients were still alive compared with 11% of men
that received the placebo vaccine." Tripling the survival rate three years
out seems like exciting news to me.

Alex